304 related articles for article (PubMed ID: 35641200)
1. Immune Checkpoint Inhibitor-related New-onset Thyroid Dysfunction: A Retrospective Analysis Using the US FDA Adverse Event Reporting System.
Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X
Oncologist; 2022 Mar; 27(2):e126-e132. PubMed ID: 35641200
[TBL] [Abstract][Full Text] [Related]
2. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
3. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
4. The Combined Effect of Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors on Thyroid Function.
Tsai K; Ma H; Liang TZ; Xing Y; Chung S; Dorff T; Bell D; Lechner MG
Thyroid; 2024 Feb; 34(2):158-166. PubMed ID: 38069567
[No Abstract] [Full Text] [Related]
5. Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: a retrospective analysis using the FAERS.
Lu D; Yao J; Yuan G; Gao Y; Zhang J; Guo X
J Endocrinol Invest; 2022 Nov; 45(11):2131-2137. PubMed ID: 35870109
[TBL] [Abstract][Full Text] [Related]
6. Thyroid Dysfunction in Non-Small Cell Lung Cancer With Immune Checkpoint Inhibitors: A Meta-Analysis.
Lin L; Yang F; Lin G; Chen X
J Clin Pharmacol; 2023 Feb; 63(2):210-218. PubMed ID: 36083133
[TBL] [Abstract][Full Text] [Related]
7. Arrhythmic events associated with immune checkpoint inhibitors therapy: A real-world study based on the Food and Drug Administration Adverse Event Reporting System database.
Liu Y; Chen Y; Zeng Z; Liu A
Cancer Med; 2023 Mar; 12(6):6637-6648. PubMed ID: 36426382
[TBL] [Abstract][Full Text] [Related]
8. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
[TBL] [Abstract][Full Text] [Related]
9. Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer.
Muir CA; Menzies AM; Clifton-Bligh R; Tsang VHM
Thyroid; 2020 Oct; 30(10):1458-1469. PubMed ID: 32264785
[No Abstract] [Full Text] [Related]
10. Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study.
Wu L; Xu Y; Wang X; Cheng X; Zhang Y; Wang Y; Fan X; Zhao H; Liu H; Chai X; Zhang L; Wang M; Li N; Pan H; Lian X
Endocrine; 2023 Jul; 81(1):123-133. PubMed ID: 36867366
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
Kotwal A; Kottschade L; Ryder M
Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
[No Abstract] [Full Text] [Related]
12. Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Wang F; Wu X
J Clin Pharm Ther; 2022 Oct; 47(10):1576-1584. PubMed ID: 35726369
[TBL] [Abstract][Full Text] [Related]
13. Ileus in patients treated with immune checkpoint inhibitors: A retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System database.
Gao S; He Z; Zhu J; Liang D; Zhao W; Yang S; Jiang W; Qiu K; Yu X; Wu J
Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1199-1205. PubMed ID: 35689298
[TBL] [Abstract][Full Text] [Related]
14. Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: A systematic review and meta-analysis.
Yang P; Shen G; Zhang H; Zhang C; Li J; Zhao F; Li Z; Liu Z; Wang M; Zhao J; Zhao Y
Int Immunopharmacol; 2024 May; 133():111961. PubMed ID: 38608442
[TBL] [Abstract][Full Text] [Related]
15. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Chen C; Wu B; Zhang C; Xu T
Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
[TBL] [Abstract][Full Text] [Related]
16. Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
Bai X; Lin X; Zheng K; Chen X; Wu X; Huang Y; Zhuang Y
Endocrine; 2020 Sep; 69(3):670-681. PubMed ID: 32507965
[TBL] [Abstract][Full Text] [Related]
17. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
18. Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database.
Li H; Sun X; Sun D; Zhao J; Xu Z; Zhao P; Ma Z; Zhang Y
Int Immunopharmacol; 2021 Sep; 98():107818. PubMed ID: 34130149
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
[TBL] [Abstract][Full Text] [Related]
20. Clinical Characters and Influence Factors of Immune Checkpoint Inhibitor-related Thyroid Dysfunction.
Zhang Q; Jiao X; Lai X
J Clin Endocrinol Metab; 2023 Oct; 108(11):2916-2923. PubMed ID: 37183427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]